Ottawa, August 13, 2018 — Cannabis legalization in Canada is less than 75 days away. What can we expect when this happens?
Summarizes the increased risk of accidental overdose due to xylazine in Canada’s unregulated drug supply. Xylazine is a non-opioid pain reliever developed as a sedative and muscle relaxant for animals. It is being found as an adulterant in other…
Please use this form to report technical problems you are having using our site (e.g., broken links, pages that do not display properly and so on). Please do not include questions about programs and services.
Presents the Canadian Centre on Substance Use and Addiction’s submission to the Office of Legislative and Regulatory Affairs, Controlled Substances and Overdose Response Directorate at Health Canada, as part of consultations.
This publication has been archived on the CCSA website and was current when it was published. It is available for reference or research purposes.
This bulletin summarizes the most recent updates on stimulant use and related harms in Canada and the United States.
Case study summarizes the Open Doors for Lanark Children and Youth (Open Doors)’s Brain Builders Lab project.
Illustrates key context and data on policies and training related to substance use by individuals in non–safety-sensitive positions (positions that pose low or no risk to self, co-workers, the public or the environment (e.g., office staff, retail…
Summarizes the full report of the same name on the legal prescription drug crisis in Canada and includes recommendations to reduce the harms.
This event is in collaboration with the the University of British Columbia (UBC), the Centre for Addiction and Mental Health (CAMH), University Health Network (UHN), and the Mental Health Commission of Canada (MHCC).
